List of Excipients in Branded Drug BUPROPION HYDROCHLORIDE SR

Generic Drugs Containing BUPROPION HYDROCHLORIDE SR

Company	Ingredient	NDC	Excipient
Aidarex Pharmaceuticals LLC	bupropion hydrochloride	33261-449	AMMONIUM CHLORIDE
Aidarex Pharmaceuticals LLC	bupropion hydrochloride	33261-449	CELLULOSE, MICROCRYSTALLINE
Aidarex Pharmaceuticals LLC	bupropion hydrochloride	33261-449	FD&C BLUE NO. 2
Aidarex Pharmaceuticals LLC	bupropion hydrochloride	33261-449	FD&C RED NO. 40

What are the Most Frequently-Used Excipients in BUPROPION HYDROCHLORIDE SR?

# Of NDCs	Excipient
1	AMMONIUM CHLORIDE
1	CELLULOSE, MICROCRYSTALLINE
1	FD&C BLUE NO. 2
1	FD&C RED NO. 40

Bupropion Hydrochloride SR Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

Bupropion hydrochloride sustained-release (SR) is a mature, genericized oral solid dose product with limited composition-of-matter patent risk and substantial formulation sensitivity. Commercial value is concentrated in manufacturing reliability, dissolution control, tablet robustness, supply security, and differentiated packaging rather than in new active-ingredient exclusivity.

The strongest excipient strategies use a controlled-release matrix that limits dose dumping, preserves release performance across pH conditions, supports high tablet hardness, and remains compatible with direct compression or an efficient granulation process. The principal opportunities are generic supply, authorized-generic manufacturing, private-label distribution, contract development and manufacturing, and line extensions involving dose strength, pack size, or adherence-oriented packaging.

What is bupropion hydrochloride SR and how is it regulated?

Bupropion hydrochloride SR is an extended-release oral tablet containing bupropion hydrochloride, an aminoketone antidepressant and smoking-cessation active ingredient. The SR product is marketed primarily in 100 mg and 150 mg strengths, with dosing commonly administered twice daily. The maximum single dose and total daily dose are constrained because seizure risk increases with higher exposure and rapid release.

The U.S. reference products include:

Product	Active ingredient	Dosage form	Reference sponsor	U.S. regulatory status
Wellbutrin SR	Bupropion hydrochloride	Sustained-release tablet	GlaxoSmithKline historically; rights and marketing arrangements have changed	NDA-approved reference product
Zyban	Bupropion hydrochloride	Sustained-release tablet	GlaxoSmithKline historically	NDA-approved smoking-cessation product
Generic bupropion hydrochloride SR	Bupropion hydrochloride	Extended-release tablet	Multiple ANDA sponsors	Approved under the abbreviated new drug application pathway

FDA-approved bupropion products are not interchangeable across all release profiles. Immediate-release, SR, and XL products have different dosage forms, dosing schedules, pharmacokinetic profiles, and formulation requirements. An SR tablet cannot be substituted for an XL tablet solely because both contain bupropion hydrochloride.

What excipients are used in bupropion hydrochloride SR tablets?

Reference and generic products use excipient systems that control water ingress, polymer swelling, drug diffusion, tablet erosion, lubrication, and film-coating performance. Exact compositions differ by manufacturer and may be protected as trade secrets.

Common excipient categories include:

Excipient category	Representative materials	Primary function
Hydrophilic matrix former	Hypromellose, hydroxypropyl cellulose	Controls hydration, swelling, diffusion, and erosion
Binder	Povidone, hydroxypropyl cellulose	Improves granule and tablet cohesion
Diluent	Microcrystalline cellulose	Adds bulk and supports compression
Lubricant	Magnesium stearate	Reduces die-wall friction and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Coating polymer	Hypromellose	Protects the tablet and provides a printable film
Opacifier and colorant	Titanium dioxide, approved pigments	Controls appearance and light protection
Surface or polishing agent	Carnauba wax or similar materials	Improves tablet surface finish
Plasticizer or coating aid	Polyethylene glycol	Improves coating flexibility and film formation

DailyMed labeling for Wellbutrin SR and Zyban identifies several of these materials, including hypromellose, hydroxypropyl cellulose, microcrystalline cellulose, magnesium stearate, colloidal silicon dioxide, and coating-related ingredients. Generic labels show formulation differences among approved products (U.S. National Library of Medicine, 2024a, 2024b).

Which excipient functions are technically critical?

The release-controlling polymer is the most commercially important excipient. Its viscosity grade, substitution pattern, particle size, concentration, and distribution through the tablet can materially affect dissolution. A small change in polymer level can alter the release curve sufficiently to affect bioequivalence risk.

The lubricant is also important. Excess magnesium stearate can reduce wetting and slow dissolution. Insufficient lubrication can produce sticking, picking, capping, or high ejection force. The formulation must balance manufacturability against release performance.

Microcrystalline cellulose and other fillers influence tablet tensile strength, porosity, friability, and water penetration. These properties affect both dissolution and scale-up reproducibility.

Film coating generally has a lower effect on drug release than the core matrix, but coating weight, curing conditions, and polymer permeability can still influence moisture protection and stability.

What excipient strategy is strongest for bupropion hydrochloride SR?

A robust strategy is a hydrophilic matrix tablet with controlled polymer loading, a low-risk filler system, and a film coat engineered for moisture protection. The preferred formulation should be developed around comparative dissolution rather than nominal excipient percentages.

Hydrophilic matrix strategy

Hypromellose-based matrices are commercially attractive because they are widely available, pharmacopeial, scalable, and familiar to generic manufacturers. They can support direct compression or wet granulation and have extensive regulatory precedent.

Hydroxypropyl cellulose may be used as a binder or matrix modifier. Its contribution depends on molecular weight and concentration. Combining it with hypromellose can adjust gel strength and release kinetics without relying on a single polymer grade.

A polymer blend can provide greater process flexibility than a single-polymer system, but it increases characterization requirements. The sponsor must demonstrate that polymer substitution does not change dissolution, impurity formation, or in vivo performance.

Direct-compression strategy

Direct compression can reduce processing steps, solvent use, drying time, and manufacturing cost. It is commercially attractive when the active ingredient and excipients have suitable flow, compressibility, and segregation behavior.

The primary risks are:

• Poor content uniformity from density differences
• Variable tablet tensile strength
• Sensitivity to lubricant mixing time
• Polymer segregation
• Dissolution shifts after scale-up
• Powder-flow limitations at high drug loading

A co-processed filler or engineered cellulose system may improve flow and compactability, but the benefit must justify the higher excipient cost and potential regulatory complexity.

Wet-granulation strategy

Wet granulation can improve content uniformity, reduce segregation, and increase tablet strength. It is useful when the active pharmaceutical ingredient has poor flow or limited compactability.

The disadvantages are higher capital and operating costs, residual-moisture control, longer cycle times, and possible changes in polymer functionality. Excessive granulation liquid or drying can alter porosity and slow or accelerate release.

For a mature generic product, wet granulation is most defensible when it solves a demonstrated manufacturing problem. It is less attractive when direct compression already meets dissolution, stability, and scale-up requirements.

What dissolution controls are required for bupropion hydrochloride SR?

Dissolution is the central critical quality attribute for bupropion hydrochloride SR. The method should assess release over multiple time points and, where relevant, across more than one medium or pH condition.

Key development targets include:

Attribute	Commercial objective
Early release	Prevent excessive initial release and dose dumping
Middle-stage release	Maintain a reproducible therapeutic exposure profile
Terminal release	Avoid residual drug retention or overly rapid late release
Tablet-to-tablet variability	Maintain tight batch uniformity
Alcohol sensitivity	Demonstrate acceptable performance in relevant alcohol conditions where required
Mechanical robustness	Preserve dissolution after packaging, transport, and handling
Stability	Maintain dissolution through shelf life

Alcohol-induced dose dumping is a material risk for modified-release dosage forms. The formulation should be evaluated under relevant ethanol conditions during development, even when the final regulatory strategy depends on the applicable product-specific guidance and approved reference-product methods.

The formulation should also be tested after compression-force changes, polymer lot changes, lubricant variation, coating changes, and accelerated stability. These studies identify whether the process is robust or whether the product depends on a narrow operating window.

What patents protect bupropion hydrochloride SR products?

The original bupropion active-ingredient and sustained-release patent estate is mature. Generic entry has occurred for many years, and the primary commercial barriers are formulation development, ANDA approval, manufacturing economics, and customer access rather than basic bupropion patent exclusivity.

Historically relevant patent protection included patents covering bupropion and sustained-release formulations. The most important historical patent families expired or reached the end of their enforceable terms before the current generic market became established. Patent term adjustment, pediatric extensions, terminal disclaimers, and jurisdiction-specific events must be confirmed in USPTO and Orange Book records for any transaction or launch decision.

The current risk profile is best summarized as follows:

IP category	Current commercial relevance
Bupropion chemical composition	Low for conventional U.S. generic entry
Original SR formulation claims	Generally expired or no longer a principal barrier
New excipient combinations	Potentially relevant if novel and non-obvious
Manufacturing process claims	Possible barrier if narrowly drafted and enforceable
Tablet appearance or packaging	Limited protection unless tied to valid trade dress or design rights
Method-of-use claims	Limited relevance to a conventional SR generic when use patents have expired or are not listed
Trade secrets	Important for reference-product process parameters and release control

A sponsor should not assume that an excipient substitution is free of patent risk. A new matrix architecture, abuse-deterrent feature, multiparticulate system, or unusual release profile could create a new patent position. The same innovation could also create a regulatory requirement for additional clinical or bridging work.

What is the Orange Book status of bupropion hydrochloride SR?

Bupropion hydrochloride SR products are regulated through FDA-approved NDAs and ANDAs. The Orange Book identifies reference listed drugs, approved dosage forms, therapeutic equivalence evaluations, and listed patents or exclusivity where applicable (FDA, 2024a).

For a generic sponsor, the relevant regulatory pathway is generally an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the applicable reference product. The filing strategy may include a Paragraph III certification for an unexpired patent with delayed launch or a Paragraph IV certification challenging a listed patent. Given the age of the SR reference products and the established generic market, a new entrant is more likely to face product-specific regulatory and commercial execution issues than a live core patent blockade.

Orange Book review should cover:

1. The exact reference listed drug.
2. The strength and dosage form.
3. Patent listings and expiration dates.
4. Therapeutic equivalence codes.
5. Any product-specific FDA guidance.
6. Whether the intended product is SR rather than XL or immediate release.

When does bupropion hydrochloride SR lose exclusivity?

Core exclusivity for bupropion hydrochloride SR has already expired in the United States. The market has multiple approved generic manufacturers, which confirms that the principal reference-product exclusivity period is no longer active.

Milestone	Commercial effect
Original NDA approval in the 1990s	Established reference-product status
Historical formulation patent period	Delayed or shaped early generic entry
Generic ANDA approvals	Opened competition in bupropion SR
Current market	Mature generic competition with price pressure
Future reformulation	Could create separate patent or regulatory exclusivity only if legally and clinically supported

A new product cannot obtain meaningful exclusivity merely by changing a conventional filler or coating color. Potentially protectable innovation would need to provide a technically meaningful and legally defensible result, such as improved dose-dumping resistance, a distinct pharmacokinetic profile, reduced food effect, improved stability, or a validated manufacturing advantage.

Which companies are challenging bupropion hydrochloride SR products?

The U.S. market includes multiple generic manufacturers and distributors. Company participation changes over time because ANDAs may be transferred, discontinued, relaunched, or marketed through private-label arrangements.

The competitive group has historically included large generic suppliers, specialty generic companies, and contract manufacturers. FDA’s Drugs@FDA and Orange Book records are the authoritative sources for current applicant and marketing status (FDA, 2024b).

The relevant competitive dimensions are:

• Approved strength and package configuration
• Current commercial availability
• Wholesale acquisition cost
• National wholesaler access
• Shortage history
• Manufacturing site continuity
• Private-label and authorized-generic relationships
• Ability to support Medicaid, Medicare, and institutional contracts

The number of approved ANDAs does not equal the number of active commercial competitors. A product may remain approved but have limited or no current distribution.

What generic entry risks exist for bupropion hydrochloride SR?

Generic entry risk is operational rather than primarily patent-driven. The main failure modes are dissolution mismatch, bioequivalence failure, scale-up variability, supply interruptions, and excessive price competition.

Regulatory risks

Bupropion products have a narrow tolerance for release variability because rapid release can increase systemic exposure and seizure risk. A formulation that passes a single development dissolution profile but performs poorly under manufacturing variation is commercially weak.

The sponsor should control:

• Polymer grade and supplier changes
• Active-ingredient particle-size distribution
• Granulation endpoint
• Compression force
• Tablet hardness and porosity
• Lubrication time
• Coating weight
• Packaging moisture protection
• Stability-indicating dissolution

Manufacturing risks

The active ingredient and matrix polymers can generate flow and segregation problems. Scale-up can change shear, residence time, granule density, and drying behavior. These changes may shift dissolution without changing the nominal formula.

A dual-source strategy for hypromellose, microcrystalline cellulose, and magnesium stearate can reduce supply risk, but every alternate source requires comparability work. Excipient supply qualification is particularly important for polymers because viscosity and substitution differences can alter release.

Commercial risks

Bupropion hydrochloride SR is a mature product with limited pricing power. A new generic entrant may face rapid price erosion unless it has a differentiated channel, reliable supply, a low-cost manufacturing platform, or a strategic customer contract.

What commercial opportunities exist for bupropion hydrochloride SR excipients?

Low-cost generic platform

The largest opportunity is a robust, low-cost SR tablet that uses widely available compendial excipients and a short manufacturing process. Direct compression is attractive when it can meet content uniformity and dissolution requirements.

Second-source and supply-resilience programs

Reference and generic manufacturers may pay for qualified second sources of critical polymers and lubricants. A supplier that can provide consistent viscosity, particle size, microbial quality, and regulatory documentation can capture value even without a novel excipient.

Private-label and institutional supply

Hospitals, correctional systems, public-health programs, and pharmacy chains may seek stable supply of bupropion SR. Packaging configurations, serialization capability, and dependable fill-finish capacity can be as important as formulation novelty.

Adherence-oriented packaging

Bupropion SR is generally dosed more than once daily. Calendar blister packs, unit-dose packaging, and patient-specific packaging can support adherence and reduce medication errors. These opportunities are commercial and packaging-led, not necessarily formulation-led.

Abuse-deterrent or alcohol-resilient formulations

An excipient platform that reduces rapid release under alcohol exposure or mechanical manipulation could support differentiated development. It would require strong comparative data, a clear regulatory rationale, and a defensible patent position. Conventional polymer substitution alone is unlikely to establish durable market exclusivity.

Lifecycle reformulation

Potential lifecycle products include:

• Lower-pill-burden dosage regimens
• Modified tablet sizes for swallowing
• Improved moisture stability
• Reduced tablet friability
• Pediatric or geriatric administration concepts, subject to clinical and regulatory feasibility
• Combination packaging with smoking-cessation support materials

A new release profile would likely fall outside a simple generic strategy and could require a 505(b)(2) application or another FDA-supported development pathway, depending on the product design and claims.

How does bupropion hydrochloride SR compare with bupropion XL?

Attribute	Bupropion SR	Bupropion XL
Typical dosing frequency	Twice daily	Once daily
Formulation objective	Controlled release over a shorter interval	Extended release over approximately a full dosing day
Excipient sensitivity	High	High, with greater dependence on long-duration release control
Generic market maturity	Mature	Mature, but formulation differences are more pronounced
Substitution	Not automatically interchangeable with XL	Not automatically interchangeable with SR
Commercial opportunity	Cost-efficient supply and adherence packaging	Once-daily convenience and differentiated delivery systems

SR and XL products should be treated as separate development targets. An SR formulation cannot be converted to XL by simply increasing polymer content. The release mechanism, tablet architecture, bioequivalence program, labeling, and regulatory reference product differ.

What patent litigation and settlement issues affect bupropion hydrochloride SR?

The major patent disputes associated with bupropion sustained-release products were tied to early generic entry and historical formulation patents. The current market is characterized by established generic availability rather than an active, high-value patent battle over conventional SR tablets.

Settlement agreements, where they existed, would have been most relevant during the original generic-entry period. Their commercial effect declines after the underlying patents expire, although settlement terms can still matter in historical litigation analysis or damages review.

For a current transaction, the practical diligence priorities are:

• Live Orange Book patents
• ANDA litigation records under the Hatch-Waxman Act
• Product-specific manufacturing patents
• Pending patent applications for differentiated release systems
• Paragraph IV litigation involving any new formulation
• Freedom-to-operate analysis for the intended excipient architecture

Is there biosimilar risk for bupropion hydrochloride SR?

No. Bupropion hydrochloride SR is a chemically synthesized small-molecule tablet, not a biologic. Biosimilar competition does not apply. Competitive entry occurs through generic drug approval, primarily under the ANDA pathway, rather than through the Public Health Service Act biosimilar pathway.

What geographic markets offer opportunities for bupropion SR excipients?

The United States is a mature, price-sensitive market with strong demand for regulatory-grade excipients and reliable generic supply. Europe, Canada, Australia, and selected Latin American markets also have established bupropion products, but approval requirements, reference products, labeling, and substitution rules differ.

Excipient suppliers should prioritize markets where:

• Modified-release products have high generic penetration
• Local manufacturers rely on imported polymers
• Regulatory authorities require extensive excipient documentation
• Supply interruptions create substitution demand
• Contract manufacturers serve multiple jurisdictions from one validated process

Global expansion requires control of pharmacopeial compliance, nitrosamine and elemental-impurity documentation where applicable, residual solvents, microbial limits, and region-specific excipient acceptance.

How strong is the patent estate for bupropion hydrochloride SR?

The patent estate for a conventional bupropion hydrochloride SR tablet is weak as a source of new market exclusivity because the foundational product and formulation protection is old and generic competition is established.

Patent strength is higher for a genuinely differentiated delivery platform:

Innovation	Potential patent strength	Commercial value
Alternative filler	Low	Manufacturing optimization
New lubricant level	Low	Process improvement
Polymer ratio adjustment	Low to moderate	Release tuning, limited exclusivity
Alcohol-resistant matrix	Moderate to high	Possible differentiated product
Novel once-daily delivery system	Moderate to high	Lifecycle product opportunity
Multiparticulate or coated-particle system	Moderate	Potential formulation and manufacturing claims
New combination product	Variable	Depends on clinical and use claims

The strongest claims would combine composition, release performance, manufacturing parameters, and measurable technical effects. A patent covering only an obvious excipient substitution would be vulnerable to validity challenges.

Key Takeaways

• Bupropion hydrochloride SR is a mature generic product with no meaningful biosimilar risk.
• The commercial center of gravity is formulation robustness, not core patent exclusivity.
• Hypromellose, hydroxypropyl cellulose, microcrystalline cellulose, povidone, colloidal silicon dioxide, and magnesium stearate are common excipient tools.
• Polymer grade, lubricant level, porosity, and compression conditions directly affect dissolution.
• Direct compression offers the strongest cost proposition when powder flow and content uniformity are adequate.
• Wet granulation is justified when it improves manufacturability or uniformity enough to offset added cost.
• Generic entry is constrained mainly by bioequivalence, dose-dumping control, supply reliability, and price erosion.
• Commercial opportunities include low-cost generic supply, second-source excipient programs, private-label distribution, institutional contracts, and adherence-oriented packaging.
• New exclusivity would require a technically differentiated delivery system, not a routine excipient substitution.
• SR and XL products require separate formulation, bioequivalence, labeling, and commercial strategies.

Frequently Asked Questions

Can bupropion hydrochloride SR tablets use different excipients from Wellbutrin SR?

Yes. ANDA applicants may use different inactive ingredients if the formulation meets FDA requirements, remains pharmaceutically equivalent, and demonstrates bioequivalence. Differences must not compromise safety, performance, dissolution, or product quality.

Which polymer is best for bupropion SR release control?

Hypromellose is usually the most practical starting point because it has broad regulatory precedent and scalable performance. The optimal polymer depends on viscosity grade, concentration, particle properties, compression process, and target dissolution profile.

Is bupropion hydrochloride SR a good candidate for direct compression?

It can be, provided the active ingredient and excipient blend deliver acceptable flow, content uniformity, tablet strength, and dissolution. Direct compression is commercially attractive because it reduces processing steps and operating cost.

Can a new bupropion SR excipient combination receive patent protection?

Potentially, but routine substitutions are unlikely to provide strong protection. Patent value is higher when the combination produces a demonstrated technical effect, such as improved alcohol resistance, reduced variability, enhanced stability, or a distinct pharmacokinetic profile.

What is the largest commercial risk for a new bupropion SR generic?

The largest risk is failure to maintain the reference-product dissolution and exposure profile during scale-up and commercial manufacturing. Once approved, price erosion and unreliable supply can determine profitability more than patent competition.

References

1. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book

2. U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. National Library of Medicine. (2024a). DailyMed: Wellbutrin SR bupropion hydrochloride tablet, film coated, extended release. https://dailymed.nlm.nih.gov/

4. U.S. National Library of Medicine. (2024b). DailyMed: Zyban bupropion hydrochloride tablet, film coated, extended release. https://dailymed.nlm.nih.gov/

5. U.S. Food and Drug Administration. (2024c). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. https://www.fda.gov/regulatory-information/search-fda-guidance-documents

6. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.